Project Grant R56AI189694
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $605K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Albany, NY 12208, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Brigham & Women's Hospital Inc. $760,700 on April 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the immune regulatory role of reactive oxygen species in sepsis. The research elucidates how reactive oxygen species modulate interleukin-1 beta bioactivity in sepsis and tests combined treatment with N-acetylcysteine and anakinra (an IL-1 receptor antagonist) to attenuate sepsis...
- The National Institute of Allergy and Infectious Diseases awarded Albany Medical College $633,136 on July 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate lung protective immunity elicited by a parental Yersinia-vesicle vaccine against pneumonic plague. The award funds research to decipher immune mechanisms in the lung following immunization with the MV46-LCRV vaccine candidate and upon pulmonary Yersinia pestis challenge. The project examines how...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $192,330 on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of intestinal microbiota in sepsis mortality. The project will elucidate mechanisms by which gut microbial dysbiosis influences sepsis outcomes through a five-year research effort running through May 31, 2031, at Yale's New Haven, Connecticut location. The research combines microbiota...
- The National Institute of Allergy and Infectious Diseases awarded Albany Medical College $451,000 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of Wnt/β-catenin signaling in alveolar epithelial repair during tuberculosis infection. The research addresses how chronic type I interferon signaling suppresses Wnt/β-catenin activity and impairs lung regeneration in tuberculosis-susceptible mice. The project encompasses three aims:...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $452,375 on June 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify transcription factors that promote pulmonary infection by opportunistic pathogens. The recipient will conduct research to determine how the transcription factor RpoN responds to environmental signals in Pseudomonas aeruginosa and Klebsiella pneumoniae, and how...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded the University of Rochester $634,882 on August 19, 2026, as a Project Grant (R01AI201741) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into immunomodulation for treatment and prophylaxis of Pneumocystis pneumonia (PCP), a life-threatening fungal infection prevalent in immunocompromised...
- The National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services National Institutes of Health, awarded $246,000 to Albany Medical College on May 1, 2026, for a Project Grant (R21AI198413) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research to investigate the role of human Fc gamma receptor I (hFcγRI) in cross-presentation and CD8 T-cell responses in the respiratory mucosa. The project...
- The National Institute of Allergy and Infectious Diseases awarded Virginia Polytechnic Institute & State University $112,256 on April 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the epigenetic basis of monocyte exhaustion memory following sepsis. The research addresses immune dysfunction persisting in sepsis survivors, specifically monocyte exhaustion—a state combining paradoxical pro-inflammatory and immunosuppressive gene expression...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital $473,937 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 25, 2025, for a project period extending through June 30, 2027. The award supports development of a novel point-of-care liquid biopsy diagnostic tool for early detection of sepsis-associated organ damage. The project leverages the institution's pioneering liquid biopsy...
- The National Institute of Allergy and Infectious Diseases awarded New York University $742,364 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate autolysin control pathways in Pseudomonas aeruginosa. The research examines how bacteria regulate cell wall-degrading enzymes (autolysins) to control their activity during cell growth and division. Pseudomonas aeruginosa serves as the model organism because it causes serious human infections...